Altoprev is a drug owned by Covis Pharma Gmbh. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2018. Details of Altoprev's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6080778 | Methods for decreasing beta amyloid protein |
Mar, 2018
(6 years ago) |
Expired
|
| US5916595 | HMG co-reductase inhibitor |
Dec, 2017
(7 years ago) |
Expired
|
| US6485748 | Once daily pharmaceutical tablet having a unitary core |
Dec, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Altoprev is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Altoprev's family patents as well as insights into ongoing legal events on those patents.
Altoprev's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Altoprev's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 23, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Altoprev Generic API suppliers:
Lovastatin is the generic name for the brand Altoprev. 9 different companies have already filed for the generic of Altoprev, with Aurobindo Pharma Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Altoprev's generic
Alternative Brands for Altoprev
Altoprev which is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease., has several other brand drugs using the same active ingredient (Lovastatin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lovastatin, Altoprev's active ingredient. Check the complete list of approved generic manufacturers for Altoprev
About Altoprev
Altoprev is a drug owned by Covis Pharma Gmbh. It is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease. Altoprev uses Lovastatin as an active ingredient. Altoprev was launched by Covis in 2002.
Approval Date:
Altoprev was approved by FDA for market use on 26 June, 2002.
Active Ingredient:
Altoprev uses Lovastatin as the active ingredient. Check out other Drugs and Companies using Lovastatin ingredient
Treatment:
Altoprev is used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease.
Dosage:
Altoprev is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 10MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 40MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 60MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |